Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,897 signal articles · 188 in last 24h · 157,635 total before filter · latest 3h ago
188last 24h
867last 7d
140● bullish (7d)
81● bearish (7d)
214publishers
AllMacro197Earnings142M&A102Regulatory18Product16Analyst24
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons to Avoid STZ and 1 Stock to Buy Instead
StockStory41d agobullish
3 Reasons to Avoid STZ and 1 Stock to Buy Instead

Over the last six months, Constellation Brands’s shares have sunk to $130.62, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 13.1% gain. This might have investors contemplating their next move.

30-Year Bond Yields Ease, Suggesting Dip-Buying
Barrons.com41d agobullish
30-Year Bond Yields Ease, Suggesting Dip-Buying

The long bond selloff has taken a pause as Treasury yields trade largely flat, following a surge that took them to multi-year highs. The 30-year Treasury yield was trading at 5.30%, a slight pullback from Monday's settlement value of 5.31%. Falling yields mean bond prices have risen.

Johnson & Johnson (JNJ) Wins FDA Clearance For AI Powered MONARCH QUEST 3
Simply Wall St.41d agobullish
Johnson & Johnson (JNJ) Wins FDA Clearance For AI Powered MONARCH QUEST 3

Johnson & Johnson (NYSE: JNJ) received FDA clearance for its MONARCH QUEST 3 bronchoscopy system, a software update to its robotic assisted bronchoscopy platform. The update introduces AI powered tools for procedure planning and lung nodule segmentation within Johnson & Johnson's MedTech portfolio. The clearance expands Johnson & Johnson's capabilities in minimally invasive diagnostics and treatment in robotic assisted bronchoscopy. New digital ecosystem features are designed to support...

3 Reasons FORM is Risky and 1 Stock to Buy Instead
StockStory41d agobullish
3 Reasons FORM is Risky and 1 Stock to Buy Instead

FormFactor has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.1%, reaching $138.29 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Bond yields surge, presenting challenge for Fed ahead of Jackson Hole
Yahoo Finance Video41d agobullishVIDEO
Bond yields surge, presenting challenge for Fed ahead of Jackson Hole

Global bond yields (^TYX, ^TNX, ^FVX) continue to spike, raising more concerns for US investors ahead of the Federal Reserve's Jackson Hole Economic Policy Symposium. Roundhill Investments CEO Dave Mazza comes on Market Catalysts to discuss how investors may be getting "a little bit spooked" by this surge.